Abstract
Nature Reviews Cancer 15, 347–360 (2015) Nai-Kong V. Cheung and Steven M. Larson have now declared competing interests that were not stated in the version of this article that was originally published. The following competing interests statement has now been added to the online version: “S.M.L. has ownership interest (including patents) in nanoparticle constructs of C-DOTs, use of mAB A33, and small molecular radio label drugs in Dasatinib and the HSP 90 inhibitor PUH71 and kinetics of immunoPET localization to tumours.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
